Memory Alzheimer’s Disease Candidate Shows Cognitive Benefit In Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm expects Roche to make a decision on an option for the nicotinic alpha-7 receptor partial agonist in the first half of 2008.